Wednesday, July 8, 2026

pharma · Carcinoma, Non-small-cell Lung · Type 2 Diabetes Mellitus · LGND

LIGAND PHARMACEUTICALS

Ligand Pharmaceuticals is a pharma organization headquartered in Jupiter, USA. It trades on NYSE under ticker LGND. Primary therapeutic focus areas include Carcinoma, Non-small-cell Lung, Type 2 Diabetes Mellitus, Sarcom

555 Heritage Dr, Suite 200, Jupiter, Florida 33458, US HQ
1987 Founded
130 Employees
Public company Type
LGND · NYSE Ticker
Company details
Status
Public
HQ
555 Heritage Dr, Suite 200, Jupiter, Florida 33458, US
Founded
1987
Employees
130
Programs
34
Drugs
25
Patents
133
Clinical program

Bexarotene

Phase 2 · small molecule · Sarcoma, Kaposi

Bexarotene for Sarcoma, Kaposi is a Phase 2 program (small_molecule) at LIGAND PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

← All LIGAND PHARMACEUTICALS INC projects Phase 2 small molecule completed

Internal code 287A

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
LIGAND PHARMACEUTICALS INC
Phase
Phase 2
Modality
small_molecule
Indication
Sarcoma, Kaposi
Status
completed
Trials
1